Product Liability Reform: HB 1 (1987).
Provides that a product’s design is not defective if: (1)
Provides that a product’s design is not defective if: (1) an injury occurs due to the inherent characteristics of a product, where the characteristics are recognized by the ordinary person with ordinary knowledge common to the community; or (2) an injury occurs because of a design which is state of the art, unless the manufacturer acted unreasonably in introducing the product into trade or commerce. Provides that a product is not defective due to lack of warnings if the risk is open and obvious or is a risk that is a matter of common knowledge. Establishes a complete defense for manufacturers and sellers of ethical drugs and/or devices if they have supplied adequate warnings to learned intermediaries, unless the FDA requires additional warnings. Provides that a drug manufacturer shall not be liable for punitive damages if the drug was approved by the FDA.
Latest News
View all news
ATRA Calls for Veto of S.B. 410 to Protect Michigan’s Economic Future
This shift is not in the best interests of consumers, manufacturers, or the state as a whole
Michigan Legislature Looks to Expand Liability, ATRA Urges Caution
Michigan lawmakers must consider the unintended consequences of expanding liability
Mass Tort Machine Exposed by Trial Lawyer Playbook Report
The Trial Lawyer Playbook report serves as a call to action, promoting transparency, accountability, and fairness in the legal system.
Congressional Hearing on Bankruptcy to Address Mass Tort Litigation
ATRA Reiterates Support for Chapter 11 Bankruptcy Use to Address Mass Tort Litigation, Urges Meaningful Dialogue Amid Senate Judiciary Committee Hearing
Climate Lawsuits Don’t Belong In State Courts
By maintaining the clear distinction between the judiciary and policymaking, the court can help us navigate this critical issue with prudence and responsibility, safeguarding a sustainable future for all.
House Oversight Hearing on Third-Party Litigation Financing Applauded by ATRA
The lack of oversight and transparency around third-party litigation funding threatens the integrity of our legal system